Pegcetacoplan
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
Feb 23, 2015 → Oct 22, 2018
NCT ID
NCT02264639About Pegcetacoplan
Pegcetacoplan is a phase 1 stage product being developed by Apellis Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT02264639. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729062 | Pre-clinical | Completed |
| NCT07020832 | Phase 3 | Recruiting |
| NCT06161584 | Pre-clinical | Active |
| NCT05809531 | Phase 3 | Active |
| NCT05067127 | Phase 3 | Completed |
| NCT04572854 | Phase 2 | Active |
| NCT04901936 | Phase 2 | Recruiting |
| NCT03531255 | Phase 3 | Active |
| NCT03593200 | Phase 2 | Completed |
| NCT03465709 | Phase 1/2 | Terminated |
| NCT02588833 | Phase 1 | Completed |
| NCT02503332 | Phase 2 | Completed |
| NCT02264639 | Phase 1 | Completed |
| NCT02461771 | Phase 1 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |